ムラガキ ヨシヒロ   MURAGAKI Yoshihiro
  村垣 善浩
   所属   研究施設 研究施設
   職種   教授
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Modified fractal analysis of methionine positron emission tomography images for predicting prognosis in newly diagnosed patients with glioma.
掲載誌名 正式名:Nuclear medicine communications
略  称:Nucl Med Commun
ISSNコード:0143-3636
掲載区分国外
巻・号・頁 39(12),1165-1173頁
著者・共著者 NAKAJIMA Reiko†*, NAGAO Michinobu, OHASHI Ryoko, MURAGAKI Yoshihiro, NITTA Masayuki, MARUYAMA Takashi, KOMORI Takashi, ABE Kouichiro, KAWAMATA Takakazu, SAKAI Shuji
発行年月 2018/12
概要 OBJECTIVE: To assess intratumoural metabolic heterogeneity using modified fractal analysis and to determine its prognostic significance in patients with glioma. PATIENTS AND METHODS: A total of 57 patients with newly diagnosed glioma who underwent methionine PET-computed tomography between August 2012 and January 2017 were enrolled. The requirement for informed consent was waived for this retrospective study. Tumour-to-normal tissue ratio, metabolic tumour volume, total lesion methionine uptake and modified fractal dimension (m-FD) were calculated for each tumour using methionine PET-computed tomography. Associations between these indices and tumour grade and overall survival were analysed. RESULTS: Overall, eight patients had grade II, 20 had grade III and 29 had grade IV tumours. The tumour-to-normal tissue ratios of grade III and grade IV tumours were significantly greater than that of grade II tumours. The metabolic tumour volume and total lesion methionine uptake of grade III tumours were significantly greater than those of grade II and grade IV tumours. The m-FD of grade IV tumours was significantly greater than those of grade II and grade III tumours. A total of 47 patients were followed up, and their prognoses were evaluated. Only the m-FD was significantly associated with a poor prognosis (P<0.05). Multivariate analyses identified age (>58 years) (hazard ratio: 5.73; 95.0% confidence interval: 1.4-29.9; P=0.015) and the m-FD (>0.87) (hazard ratio: 4.80; 95.0% confidence interval: 1.12-32.9; P=0.033) as independent prognostic factors for overall survival. CONCLUSION: Intratumoural metabolic heterogeneity is a useful imaging biomarker in patients with glioma.
DOI 10.1097/MNM.0000000000000917
PMID 30247386